Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: Results of the blood and marrow transplant clinical trials network protocol 0303

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 9, 2011, Pages 1343-1351

  Devine, Steven M ^a   Carter, Shelly ^b   Soiffer, Robert J ^c   Pasquini, Marcelo C ^d   Hari, Parameswaran N ^d   Stein, Anthony ^e   Lazarus, Hillard M ^f   Linker, Charles ^g   Stadtmauer, Edward A ^h   Alyea, Edwin P ^c   Keever Taylor, Carolyn A ^d   O'Reilly, Richard J ⁱ  

^a OHIO STATE UNIVERSITY   (United States)

^b EMMES CORPORATION   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

AML; GVHD; Prophylaxis; Transplantation

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGRAFT; ARTICLE; CD34 SELECTION; CHEMORADIOTHERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HLA MATCHING; HUMAN; INCIDENCE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MULTICENTER STUDY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; T CELL DEPLETION; WHOLE BODY RADIATION;

ADULT; ANTIGENS, CD34; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MIDDLE AGED; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; RISK; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 79960270124     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.02.002     Document Type: Article

References (40)

1. Copelan E.A. Hematopoietic stem-cell transplantation. N Engl J Med 2006, 354:1813-1826.
2. Cornelissen J.J., van Putten W.L.J., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 2007, 109:3658-3666.
3. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
4. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000, 96:4075-4083.
5. Suciu S., Mandelli F., de Witte T., et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003, 102:1232-1240.
6. Lee S.J., Vogelsang G., Flowers M.E.D. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
7. Messerer D., Engel J., Hasford J., et al. Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica 2008, 93:826-833.
8. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative Group.
9. Champlin R.E., Passweg J.R., Zhang M.-J., et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000, 95:3996-4003.
10. Ho V.T., Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001, 98:3192-3204.
11. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005, 23:3447-3454.
12. Handgretinger R., Klingebiel T., Lang P., et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001, 27:777-783.
13. Jakubowski A.A., Small T.N., Young J.W., et al. T cell-depleted stem cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood 2007, 110:4552-4559.
14. Papadopoulos E.B., Carabasi M.H., Castro-Malaspina H., et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998, 91:1083-1090.
15. Soiffer R.J., Fairclough D., Robertson M., et al. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 1997, 89:3039-3047.
16. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
17. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
18. Niesters H.G.M., van Esser J., Fries E., et al. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 2000, 38:712-715.
19. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
20. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
21. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
22. Baldus C.D., Thiede C., Soucek S., et al. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol 2006, 24:790-797.
23. Gale R.E., Green C., Allen C., et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111:2776-2784.
24. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
25. Gooley T.A., Leisenring W., Crowley J., et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
26. Bornhauser M., Platzbecker U., Theuser C., et al. CD34+-enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back. Br J Haematol 2002, 118:1095-1103.
27. Elmaagacli A.H., Peceny R., Steckel N., et al. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 2003, 101:446-453.
28. Kernan N.A., Collins N.H., Juliano L., et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986, 68:770-773.
29. Cooke K.R., Yanik G. Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease?. Bone Marrow Transplant 2004, 34:753-765.
30. Fukuda T., Hackman R.C., Guthrie K.A., et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003, 102:2777-2785.
31. Ho V.T., Weller E., Lee S.J., et al. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001, 7:223-229.
32. Junghanss C., Marr K.A., Carter R.A., et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002, 8:512-520.
33. van Burik J.-A.H., Carter S.L., Freifeld A.G., et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:1487-1498.
34. Landgren O., Gilbert E.S., Rizzo J.D., et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009, 113:4992-5001.
35. Schlenk R.F., Dohner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
36. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991, 78:2120-2130.
37. Goldman J.M., Gale R.P., Horowitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806-814.
38. Wagner J.E., Thompson J.S., Carter S.L., et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-Cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005, 366:733-741.
39. Aversa F., Terenzi A., Carotti A., et al. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. J Clin Oncol 1999, 17:1545-1550.
40. Flowers M.E.D., Parker P.M., Johnston L.J., et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002, 100:415-419.